ClinicalTrials.gg
RecruitingNCT07364175SOLUTION-PilotUpdated Jan 29, 2026

A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

An interventional study of Tirzepatide and Anti-Hypertensive medications in Hypertension and Obesity & Overweight, sponsored by Cambridge University Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Cambridge University Hospitals NHS Foundation Trust · Not applicable, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 223 studies in Hypertension with a site in United Kingdom — 34 open to participants now, 43 under way, 7 of them phase 3. Hypertension · United Kingdom.

Planned enrollment
114th of 172
60 · median 125
Started
2026
with 7 others
No phase
73 of 223
13 open now
Primary completion
2027-01
later than 20 of 42 live
Registered
218th of 223
by date
Lead sponsor
7 of 223
Cambridge University Hospitals NHS Foundation Trust

Among the 223 studies in Hypertension with a site in United Kingdom, this one is the 114th largest by planned enrollment of the 172 interventional ones that give a count, is one of 8 that started in 2026, is one of 73 with no phase, reaches primary completion later than 20 of the 42 other live ones, and was the 218th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

34 of the 223 studies in Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 223 studies in Hypertension with a site in United Kingdom, or all of them as a file.
02

Study summary

Hypertension is the leading risk factor for death globally, affecting approximately 30% of adults in the United Kingdom. Obesity is also a serious and ongoing epidemic, with global obesity rates having more than tripled in men and doubled in women, since 1975. In the United Kingdom, 64% of the adult population are overweight or obese. Hypertension and obesity share a well-established association, with obesity being responsible for the development of hypertension in 40-78% of cases. In young adults, this link between body size and blood pressure (BP) is much stronger that in older adults. Since overweight and obesity are among the most common and modifiable causes of high BP, weight loss induced by lifestyle-changes is recommended for overweight or obese patients with hypertension. However, lifestyle interventions, even when successful, result in only moderate weight loss, which is not maintained in the majority of cases. A meta-analysis of randomised controlled trials demonstrated that lifestyle-interventions lead to an average net weight reduction of 5.1 kg, accompanied by a significant, but modest, \~4 mmHg reduction in BP. Weight loss interventions could play a crucial role in the treatment of obesity-related hypertension in young adults.

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, originally developed for the treatment of type 2 diabetes, are safe and clinically effective anti-obesity drugs. Recent data show a 10-20% placebo-adjusted reduction in body weight in overweight or obese adults without diabetes using the GLP-1 analogue semaglutide or the dual GLP-1/GIP receptor agonist tirzepatide, with the majority of weight loss achieved within the initial six months. The substantial weight loss induced by these drugs is accompanied by a significant reduction in BP. Two recent meta-analyses showed that semaglutide is associated with a \~5 mmHg placebo-adjusted reduction in clinic systolic BP (SBP). A sub-study of the SURMOUNT-1 trial reported a \~10 mmHg reduction in 24-h ambulatory SBP with tirzepatide. Most participants in these studies were normotensive or had well-controlled hypertension. Furthermore, antihypertensive medication use declined amongst those receiving anti-obesity drugs meaning the BP-lowering effect of weight loss, elicited by these drugs, is probably underestimated. These data suggest that the new anti-obesity drugs could be effective in managing overweight or obesity-related hypertension. Furthermore, it may be possible to cure hypertension in at least some young adults, removing the need for life-long antihypertensive treatment. However, the magnitude and time course of BP reduction elicited by these new anti-obesity drugs remain uncertain.

The primary aim of this feasibility study is to assess the extent and trajectory of BP reduction achieved through intensive weight loss in overweight or obese adults with stage 1 hypertension and compare this to current standard of care measures which uses anti-hypertensive medications and lifestyle advice. The study will utilise a modified trial within cohort approach, using patients based within the clinical pharmacology/hypertension service at Addenbrooke's Hospital, Cambridge.

03

Conditions studied

  • Hypertension
  • Obesity & Overweight

Keywords

  • hypertension
  • obesity
  • overweight
  • tirzepatide
  • GLP-1
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility criteria for randomisation

Inclusion Criteria:

  • Aged 18 to 40 years (inclusive)
  • (BMI) ≥27 kg/m2
  • Clinical diagnosis of primary (essential) hypertension as per NICE guidance
  • Unattended brachial SBP ≥135 and/or DBP ≥85 mmHg and \<160/100 mmHg
  • Maximum of one antihypertensive medication

Exclusion Criteria:

  • Anything in medical notes suggesting unsuitable in the opinion of the investigator

Eligibility criteria for participation in weight loss arm

Inclusion criteria:

  • Written
  • Aged 18 to 40 years (inclusive)
  • Body mass index ≥27 kg/m2
  • Clinical diagnosis of primary (essential) hypertension as per NICE guidance
  • Unattended brachial SBP ≥135 and/or DBP ≥85 mmHg and \<160/100 mmHg
  • Maximum of one antihypertensive medication

Exclusion criteria:

The presence of any of the following will preclude participant inclusion:

  • Known or suspected secondary hypertension
  • to any of the study drugs or
  • Currently taking drugs likely to have interactions with tirzepatide
  • Diagnosis of type 1 or type 2 diabetes mellitus or current usage of insulin or other injectable drugs for the treatment of diabetes such as but not limited to GLP-1 and GIP receptor agonists
  • Prior or planned surgical, endoscopic and/or device-based therapy treatment for obesity
  • Self-reported, intentional or unintentional, change in body weight (over \~10%) within \~three months of screening
  • Known heart failure or valvular heart disease
  • Implanted pacemaker or implantable cardioverter defibrillator (ICD)
  • Second or third-degree AV block, sino-atrial block, sick sinus syndrome
  • Known active including thyroid cancer
  • Known renal impairment (creatinine >150µmol/L)
  • Clinically significant neurological disease
  • History of scleroderma
  • Participants on anticoagulant therapy
  • Known history of pancreatitis
  • Known inflammatory bowel disease
  • History of gallstones (unless previous cholecystectomy)
  • Severe gastroparesis or gastric emptying abnormality
  • Family history of multiple endocrine neoplasia
  • Needle-phobia
  • Planned pregnancy, current pregnancy, or breastfeeding
  • Current involvement in the active treatment phase of other research studies
  • Any other clinical reason which may preclude entry in the opinion of the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Tirzepatide [weight loss arm]

    6 months of treatment with a combined GLP-1/GIP receptor agonist, tirzepatide

    Drug: Tirzepatide

  • Active comparator
    Lifestyle advice and anti-hypertensive medications [standard of Care arm]

    Drug: Anti-Hypertensive medications

Interventions

  • 2.5mg for 4 weeks, 5mg for 4 weeks, 7.5mg for 4 weeks, 10mg for 12 weeks

  • DrugAnti-Hypertensive medications

    Anti-hypertensive drug therapy as per local and national guidelines

06

What researchers measure

Primary outcomes

  1. Ambulatory systolic blood pressure

    Change in daytime ambulatory systolic blood pressure in the weight loss arm

    Time frame: Baseline to week 24

Secondary outcomes

  1. Ambulatory diastolic blood pressure

    Change in daytime ambulatory diastolic blood pressure in the weight loss arm

    Time frame: Baseline to week 24

  2. Clinic systolic blood pressure

    Changes in clinic systolic blood pressure in the weight loss arm

    Time frame: Baseline to week 24

  3. Clinic diastolic blood pressure

    Changes in clinic diastolic blood pressure in the weight loss arm

    Time frame: Baseline to week 24

  4. Clinic mean arterial pressure

    Changes in clinic mean arterial pressure in the weight loss arm

    Time frame: Baseline to week 24

  5. Unattended systolic blood pressure

    Changes in unattended systolic blood pressure in the weight loss arm

    Time frame: Baseline to week 24

  6. Unattended diastolic blood pressure

    Changes in unattended diastolic blood pressure in the weight loss arm

    Time frame: Baseline to week 24

  7. Unattended mean arterial pressure

    Changes in unattended mean arterial pressure in the weight loss arm

    Time frame: Baseline to week 24

  8. Body weight

    Changes in body weight in the weight loss arm

    Time frame: Baseline to week 24

  9. Body fat

    Changes in body fat in the weight loss arm

    Time frame: Baseline to week 24

  10. Waist:hip ratio

    Changes in waist:hip ratio in the weight loss arm

    Time frame: Baseline to week 24

  11. Cardiac output

    Changes in cardiac output in the weight loss arm

    Time frame: Baseline to week 24

  12. Peripheral vascular resistance

    Changes in peripheral vascular resistance in the weight loss arm

    Time frame: Baseline to week 24

  13. Pulse wave analysis / pulse wave velocity

    Changes in markers of pulse wave analysis and pulse wave velocity in the weight loss arm

    Time frame: Baseline to week 24

  14. Heart rate variability

    Changes in heart rate variability in the weight loss arm

    Time frame: Baseline to week 24

  15. Renin

    Changes in plasma renin in the weight loss arm

    Time frame: Baseline to week 24

  16. Aldosterone

    Changes in plasma aldosterone in the weight loss arm

    Time frame: Baseline to week 24

  17. Plasma metanephrines

    Changes in plasma metanephrines in the weight loss arm

    Time frame: Baseline to week 24

  18. Leptin

    Changes in leptin in the weight loss arm

    Time frame: Baseline to week 24

  19. Insulin

    Changes in plasma insulin in the weight loss arm

    Time frame: Baseline to week 24

  20. Lipid profile

    Changes in the lipid profile in the weight loss arm

    Time frame: Baseline to week 24

  21. HbA1C

    Changes in HbA1C in the weight loss arm

    Time frame: Baseline to week 24

  22. Estimated glomerular filtration rate

    Changes in eGFR in the weight loss arm

    Time frame: Baseline to week 24

  23. N-terminal pro-B-type natriuretic peptide

    Changes in NT-proBNP in the weight loss arm

    Time frame: Baseline to week 24

  24. Urine albumin:creatinine ratio

    Change in urine albumin:creatinine ratio in the weight loss arm

    Time frame: Baseline to week 24

  25. 24-hour urine sodium

    Change in 24-hour urine sodium in the weight loss arm

    Time frame: Baseline to week 24

  26. 24-hour urine aldosterone

    Change in 24-hour urine aldosterone in the weight loss arm

    Time frame: Baseline to week 24

  27. Antihypertensive medications

    Change in number of antihypertensive medications

    Time frame: Baseline to week 24

  28. Quality of life measures

    Changes in quality of life questionnaire scores in the weight loss arm

    Time frame: Baseline to week 24

  29. Ambulatory systolic blood pressure

    Between-group comparison in ambulatory sytolic blood pressure

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  30. Ambulatory diastolic blood pressure

    Between-group comparison in ambulatory diastolic blood pressure

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  31. Clinic systolic blood pressure

    Between-group comparison in clinic systolic blood pressure

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  32. Clinic diastolic blood pressure

    Between-group comparison in clinic diastolic blood pressure

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  33. Clinic mean arterial pressure

    Between-group comparison in clinic mean arterial pressure

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  34. Unattended systolic blood pressure

    Between-group comparison in unattended systolic blood pressure

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  35. Unattended diastolic blood pressure

    Between-group comparison in unattended diastolic blood pressure

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  36. Unattended mean arterial pressure

    Between-group comparison in mean arterial pressure

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  37. Body weight

    Between-group body weight

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  38. Body fat

    Between-group comparison in body fat

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  39. Waist:hip ratio

    Between-group comparison in waist:hip ratio

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  40. Cardiac output

    Between-group comparison in cardiac output

    Time frame: At week 24 (weight loss arm) and 6 months (standard of care arm)

  41. Peripheral vascular resistance

    Between-group comparison in peripheral vascular resistance

    Time frame: At week 24 (weight loss arm) and 6 months (standard of care arm)

  42. Pulse wave analysis / pulse wave velocity

    Between-group comparison in markers of pulse wave analysis and pulse wave velocity

    Time frame: At week 24 (weight loss arm) and 6 months (standard of care arm)

  43. Heart rate variability

    Between-group comparison in heart rate variability

    Time frame: At week 24 (weight loss arm) and 6 months (standard of care arm)

  44. Plasma renin

    Between-group comparison in plasma renin

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  45. Plasma aldosterone

    Between-group comparison in plasma aldosterone

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  46. Plasma metanephrines

    Between-group comparison in plasma metanephrines

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  47. Lipid profile

    Between-group comparison in lipid profile

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  48. HbA1C

    Between-group comparison in HbA1C

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  49. Estimated glomerular filtration rate

    Between-group comparison in eGFR

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  50. N-terminal pro-B-type natriuretic peptide

    Between-group comparison in NT-proBNP

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  51. Urine albumin:creatinine ratio

    Between-group comparison in urine albumin:creatinine ratio

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  52. 24-hour urine sodium

    Between-group comparison in 24-hour urine sodium

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  53. 24-hour urine aldosterone

    Between-group comparison in 24-hour urine aldosterone

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  54. Number of antihypertensive medications

    Between-group comparison in the number of anti-hypertensive medications

    Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)

  55. Quality of life measures

    Between-group comparison in quality of life questionnaire scores

    Time frame: At week 24 (weight loss arm) and 6 months (standard of care arm)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Following publication, the data that support the findings of this study will be available from the Chief Investigator/corresponding author upon reasonable request

Supporting information: Study protocol, Clinical study report

Access criteria: Following publication, the data that support the findings of this study will be available from the Chief Investigator/corresponding author upon reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jan 2027, 12 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 23, 2026
StartEst.
Jan 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2029
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07364175
Collaborators
National Institute for Health Research, United Kingdom
Responsible party
James Goodman (Consultant Physician and Clinical Pharmacologist, Cambridge University Hospitals NHS Foundation Trust) — Principal investigator
First posted
Jan 23, 2026
Start date
Jan 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2029 (estimated)
Last update
Jan 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion